Literature DB >> 35065582

Monitoring EBV infection, MSI, PDL-1 expression, Her-2/neu amplification as a biomarker for PD-1 inhibition in gastric cancer.

L Stanek, R Gurlich, Z Musil, L Havluj, A Whitley.   

Abstract

BACKGROUND: The anti-PD-1 monoclonal antibody pembrolizumab has been shown to be associated with a good response in patients with metastatic gastric cancer. Excellent therapeutic results of pembrolizumab have been shown in patients with tumours showing a high microsatellite instability (MSI) and Epstein-Barr virus (EBV) positivity. GOAL: This is a retrospective study of 40 bioptic specimens from the patients, who underwent gastrectomy for gastric carcinoma. The goal of the study was to identify biomarkers (EBV, MLH-1, PDL-1 expression) that are potentially relevant for selecting the patients, who may benefit from PD-1 inhibition therapy.
METHODS: Immunohistochemical (IHC) expression of PDL-1 and MSI, cytogenetic FISH amplification of the HER-2/neu gene and polymerase chain reaction of EBV RNA, including charge quantification, were performed in selected patients with metastatic or advanced gastric cancer.
RESULTS: EBV-encoded RNA was detected in nine patients. None of them exhibited Her-2 overexpression or CMV infection. PD-L1 was detected in twelve patients. Ten patients were MLH1 positive. All nine cases of EBV infection showed a high expression of PD-L1 and MLH-1 (Tab. 1, Ref. 14).

Entities:  

Keywords:  EBV infection; MSI PD-L-1 expression.; gastric cancer; molecular diagnostics

Mesh:

Substances:

Year:  2022        PMID: 35065582     DOI: 10.4149/BLL_2022_013

Source DB:  PubMed          Journal:  Bratisl Lek Listy        ISSN: 0006-9248            Impact factor:   1.278


  1 in total

1.  EBV and further emerging directions towards increased precision in gastric cancer treatment.

Authors:  Luana B C Santos; Thais F Bartelli; Diana N Nunes; Emmanuel Dias-Neto
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.